Variational AI is at the forefront of Artificial Intelligence drug discovery and we look towards a successful and lasting partnership.

Compute efficient generative AI foundation model for small molecule drug discovery start-up announces funding from leading AI and biotech investors.

Third-party investment in AI-enabled drug discovery more than doubled annually for five years, increasing from $2.4 billion in 2020 to $5.2 billion in 2021.

Merck & Co. has partnered with Variational AI to explore using artificial intelligence in drug discovery. Variational AI CEO Handol Kim says Merck will test Variational’s Enki platform in ...

Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery ...

Additional financial terms were not disclosed. According to Variational AI CEO Handol Kim, “We are thrilled to be partnering with Rakovina Therapeutics in their quest for lifesaving, cancer drugs.

VANCOUVER, British Columbia, February 20, 2025--Compute efficient generative AI foundation model for small molecule drug discovery start-up announces funding from leading AI and biotech investors.